Nature Reviews Cardiology

Article	Citations
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions	624
Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension	608
Interplay between inflammation and thrombosis in cardiovascular pathology	410
Smart wearable devices in cardiovascular care: where we are and how to move forward	376
PPAR control of metabolism and cardiovascular functions	370
Artificial intelligence-enhanced electrocardiography in cardiovascular disease management	368
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease	354
Global epidemiology of dyslipidaemias	348
Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases	326
Epidemiology of cardiovascular disease in Europe	296
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation	295
Pathophysiology of sepsis-induced cardiomyopathy	281
Global epidemiology of valvular heart disease	271
Transportation noise pollution and cardiovascular disease	246
Epicardial adipose tissue in contemporary cardiology	219
Self-powered cardiovascular electronic devices and systems	219
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis	216
Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6	214
Cellular and molecular pathobiology of heart failure with preserved ejection fraction	214
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium	196
Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes	192
Cardiovascular disease in patients with severe mental illness	186
Ceramides and other sphingolipids as drivers of cardiovascular disease	185
The role of cardiac rehabilitation in improving cardiovascular outcomes	183
Heart failure with mid-range or mildly reduced ejection fraction	179

Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms	170
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging	158
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?	155
Lifestyle interventions for the prevention and treatment of hypertension	153
Systems biology in cardiovascular disease: a multiomics approach	153
Optical coherence tomography in coronary atherosclerosis assessment and intervention	150
Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches	146
Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity	139
Sit less and move more for cardiovascular health: emerging insights and opportunities	138
Epidemiology of the inherited cardiomyopathies	136
The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy	128
Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management	126
Vascular endothelial cell development and diversity	116
Genomics of hypertension: the road to precision medicine	115
Transforming growth factor-β in myocardial disease	115
Blood pressure and its variability: classic and novel measurement techniques	111
Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease	109
High-density lipoproteins, reverse cholesterol transport and atherogenesis	107
Mechanisms and consequences of endothelial cell senescence	106
The role of cellular senescence in cardiac disease: basic biology and clinical relevance	106
Cardiac optogenetics: a decade of enlightenment	105
Genomic frontiers in congenital heart disease	105
Catheter ablation for atrial fibrillation: current indications and evolving technologies	103
Apolipoproteins in vascular biology and atherosclerotic disease	101
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development	101
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action	95
Epidemiology and prevention of venous thromboembolism	95
Applications of artificial intelligence in cardiovascular imaging	90
Climate change and cardiovascular disease: implications for global health	90
Complete versus incomplete coronary revascularization: definitions, assessment and outcomes	89
The role of mitochondrial fission in cardiovascular health and disease	89
Cardiovascular risks of climate change	88
Obesity and the risk of cardiometabolic diseases	87
Update on the pathophysiology and medical treatment of peripheral artery disease	84
Sulfide regulation of cardiovascular function in health and disease	84
Epidemiology and modifiable risk factors for atrial fibrillation	84
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia	82
RNA-targeting and gene editing therapies for transthyretin amyloidosis	82
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology	82
Branched-chain amino acids in cardiovascular disease	81
Cardiac involvement in the long-term implications of COVID-19	80
Myocardial stunning and hibernation revisited	80
Bleeding avoidance strategies in percutaneous coronary intervention	76
Clinical utility of polygenic risk scores for coronary artery disease	75
Social determinants of atrial fibrillation	72
A fresh look at coronary microembolization	72
Prevention of atherosclerosis from childhood	71
Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs	69
Plaque erosion and acute coronary syndromes: phenotype, molecular characteristics and future directions	67
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia	66

Targeted delivery of therapeutic agents to the heart	65
Immune cell profiling in atherosclerosis: role in research and precision medicine	63
Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes	62
Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications	60
Pharmacogenetics to guide cardiovascular drug therapy	59
Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies	59
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective	57
Macrophages in cardiac remodelling after myocardial infarction	57
Targeting the sarcomere in inherited cardiomyopathies	57
The evolving cardiac lymphatic vasculature in development, repair and regeneration	56
Hallmarks of cardiovascular ageing	55
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism	54
Electroimmunology and cardiac arrhythmia	52
The health digital twin: advancing precision cardiovascular medicine	51
Obstructive sleep apnoea heterogeneity and cardiovascular disease	51
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention	50
Bioengineering approaches to treat the failing heart: from cell biology to 3D printing	48
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications	48
Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management	47
Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research	45
Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease	45
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention	43
Towards precision medicine in heart failure	43
Remote monitoring and digital health tools in CVD management	41
Calcific aortic valve disease: mechanisms, prevention and treatment	41
Sirtuins in atherosclerosis: guardians of healthspan and therapeutic targets	41
The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease	40
The microtubule cytoskeleton in cardiac mechanics and heart failure	40
The contribution of the exposome to the burden of cardiovascular disease	40
The oral microbiome in the pathophysiology of cardiovascular disease	40
Repurposing drugs to treat cardiovascular disease in the era of precision medicine	39
Increasing representation and diversity in cardiovascular clinical trial populations	39
The COVID-19 pandemic: a catalyst to improve clinical trials	37
Flow-induced reprogramming of endothelial cells in atherosclerosis	37
Single-cell transcriptomics for the assessment of cardiac disease	37
Stroke prevention strategies in high-risk patients with atrial fibrillation	37
Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure	36
Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization	36
Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges	36
Cardiac fibroblasts and mechanosensation in heart development, health and disease	36
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer	36
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential	35
Hypertension in China: epidemiology and treatment initiatives	34
Improving clinical practice guidelines with implementation science	33
Interventional therapies for pulmonary embolism	32
Temporary mechanical circulatory support devices: practical considerations for all stakeholders	32
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	31
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease	31
Autonomic dysfunction and postural orthostatic tachycardia syndrome in post-acute COVID-19 syndrome	31
The role of aldehyde dehydrogenase 2 in cardiovascular disease	30
A change of heart: new roles for cilia in cardiac development and disease	29
Pathophysiology and risk factors of peripartum cardiomyopathy	29
Effects of fatty acids on T cell function: role in atherosclerosis	28
Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: a Consensus Statement from the Quantitative Cardiovascular Imaging Study Group	27
The use of new CRISPR tools in cardiovascular research and medicine	27
The need for increased pragmatism in cardiovascular clinical trials	25
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization	24
Genetics and mechanisms of thoracic aortic disease	24
Global epidemiology of acute coronary syndromes	24
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications	24
Plastics and cardiovascular disease	24
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases	24
The biology of atherosclerosis comes full circle: lessons for conquering cardiovascular disease	23
Long COVID and cardiovascular disease: a learning health system approach	21
Trained immunity in atherosclerotic cardiovascular disease	20
A role for lipophagy in atherosclerosis	20
Diversity 4.0 in the cardiovascular health-care workforce	19
RNA modifications in cardiovascular health and disease	19
Current concepts and novel targets for antiplatelet therapy	19
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thro	18
Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden	18
Cardiovascular health and disease in migrant populations: a call to action	18
Genomic enhancers in cardiac development and disease	18
PCSK9-targeted therapies: present and future approaches	18
Clarification of the definition of hypoplastic left heart syndrome	18
Genetics and genomics of arrhythmic risk: current and future strategies to prevent sudden cardiac death	17
Current and future applications of virtual reality technology for cardiac interventions	17
The bidirectional association between atrial fibrillation and myocardial infarction	17
Immune and inflammatory mechanisms in hypertension	17
Mechanisms of ryanodine receptor 2 dysfunction in heart failure	16

Clonal haematopoiesis and atherosclerosis: a chicken or egg question?	15
2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease	14
Nanotherapeutics for cardiovascular disease	14
The ongoing quest for the first total artificial heart as destination therapy	14
A pathophysiological compass to personalize antianginal drug treatment	13
Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease	13